Myriad Genetics (MYGN) officer role ends; 127,726 shares held

Myriad Genetics (MYGN) filed a Form 4/Exit noting a leadership change.

Accepted by SEC EDGAR 11/04/2025 - 04:32 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Myriad Genetics (MYGN) filed a Form 4/Exit noting a leadership change. The filing states that, effective on November 3, 2025, the reporting person no longer serves as EVP, Strategy & Transformation and therefore is no longer subject to Section 16 reporting.

The report lists 127,726 shares of common stock beneficially owned directly following the reported event. The form was filed by one reporting person.

Insider Trade Summary

Holdings reported, no transactions

Holdings

Insider Ancona Margaret

Role EVP, Strategy & Transformation

Type	Security	Shares	Price	Value
Holding	Common Stock	--	--	--

Holdings: Common Stock — 127,726 shares (Direct)

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did MYGN disclose in this Form 4/Exit filing?

It reports that the officer no longer serves as EVP, Strategy & Transformation as of November 3, 2025, and is no longer subject to Section 16 reporting.

When did the MYGN EVP Strategy & Transformation role end?

The role ended effective November 3, 2025.

How many MYGN shares does the reporting person own after the event?

The filing shows 127,726 shares of common stock beneficially owned directly.

Does this MYGN filing involve multiple reporting persons?

No. It indicates the form was filed by one reporting person.

What is the officer’s relationship to MYGN noted in the filing?

The reporting person was an Officer, titled EVP, Strategy & Transformation.

What is the stated effect on Section 16 status for the reporting person?

They are no longer subject to Section 16 reporting as of the effective date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

X

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ancona Margaret

(Last) (First) (Middle)

322 NORTH 2200 WEST

(Street)

SALT LAKE CITY UT 84116

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MYRIAD GENETICS INC [ MYGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Strategy & Transformation

3. Date of Earliest Transaction (Month/Day/Year)
11/03/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock								127,726	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

This "Exit" Form 4 is voluntarily filed to report solely that, effective on November 3, 2025, the Reporting Person no longer serves in the role of EVP, Strategy & Transformation of the Company, and therefore is no longer subject to Section 16 reporting.

	By: Justin Hunter For: Margaret Ancona	11/04/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.